- Results suggest that the extended duration of therapeutic benefit with DaxibotulinumtoxinA for Injection can produce dermal remodeling due to the prolonged period of muscle inactivity “The data ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the neuromodulator injection Daxxify for the temporary improvement of moderate to severe ...

Credit: Hugel. Letybo, an acetylcholine release inhibitor and a neuromuscular blocking agent, was approved in March 2024 based on data from three phase 3 trials. Letybo should be administered no more ...

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced positive topline efficacy ...

“Extra-strength” 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment ...

TORONTO--(BUSINESS WIRE)--Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics, today announced it received a Notice of Compliance from Health Canada for Letybo (letibotulinumtoxinA for ...

Please provide your email address to receive an email when new articles are posted on . 43.9% of patients experienced a treatment-emergent adverse event. Only 18.2% were treatment related. Efficacy ...

South Korea's market leading neurotoxin in aesthetics set to launch in the second half of 2024. NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a ...